Physician profile
Michael Ibach
NPI 1053362723
$3,624.52
in general payments reported to CMS, 2019-2025
24 companies · $299 in 2025
The $299 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2020: $1,543 · 2021: $294 · 2022: $379 · 2023: $298 · 2024: $655 · 2025: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,047 · Travel and Lodging: $106 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,046.73 |
| Travel and Lodging | $106.25 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adare Pharmaceuticals, INC. | $1,459.03 | 2020 | |
| Janssen Biotech, INC. | $357.39 | 2021-2025 | Stelara, Remicade, Simponi Aria |
| Abbvie INC. | $303.53 | 2019-2025 | |
| Enterra Medical, INC. | $206.61 | 2024 | |
| Genzyme Corporation | $197.49 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $178.78 | 2019-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals Lp | $158.70 | 2024 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $133.19 | 2025 | Dupixent |
| Merck Sharp & Dohme LLC | $92.94 | 2019-2023 | Dificid |
| Takeda Pharmaceuticals U.S.A., INC. | $63.39 | 2019-2024 | Eohilia |
| Pfizer INC. | $61.95 | 2023 | |
| Allergan, INC. | $55.20 | 2019-2020 | |
| Celgene Corporation | $52.02 | 2022-2024 | Zeposia |
| Olympus America INC. | $49.83 | 2022 | |
| Medtronic, INC. | $46.97 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $44.50 | 2019-2021 | |
| Braintree Laboratories, INC. | $40.72 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $25.34 | 2022 | |
| Aimmune Therapeutics, INC. | $23.46 | 2024 | |
| Daiichi Sankyo INC. | $22.60 | 2020 | |
| Ambu INC. | $19.62 | 2021 | |
| Nestle Healthcare Nutrition INC. | $15.65 | 2021 | |
| Ardelyx, INC. | $15.61 | 2025 | Ibsrela |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ibach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.